S&P 500   2,999.25 (+1.12%)
DOW   27,048.67 (+0.98%)
QQQ   193.52 (+1.27%)
AAPL   235.97 (+0.04%)
FB   189.55 (+3.42%)
MSFT   141.59 (+1.45%)
GOOGL   1,240.70 (+1.88%)
AMZN   1,760.54 (+1.39%)
CGC   20.15 (+6.84%)
NVDA   198.44 (+6.39%)
MU   46.44 (+3.52%)
BABA   176.45 (+3.09%)
TSLA   259.33 (+0.92%)
T   37.94 (+1.25%)
ACB   3.83 (+9.13%)
NFLX   284.92 (-0.21%)
BAC   29.99 (+2.92%)
GILD   65.62 (+1.71%)
DIS   129.61 (-0.07%)
S&P 500   2,999.25 (+1.12%)
DOW   27,048.67 (+0.98%)
QQQ   193.52 (+1.27%)
AAPL   235.97 (+0.04%)
FB   189.55 (+3.42%)
MSFT   141.59 (+1.45%)
GOOGL   1,240.70 (+1.88%)
AMZN   1,760.54 (+1.39%)
CGC   20.15 (+6.84%)
NVDA   198.44 (+6.39%)
MU   46.44 (+3.52%)
BABA   176.45 (+3.09%)
TSLA   259.33 (+0.92%)
T   37.94 (+1.25%)
ACB   3.83 (+9.13%)
NFLX   284.92 (-0.21%)
BAC   29.99 (+2.92%)
GILD   65.62 (+1.71%)
DIS   129.61 (-0.07%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Aimmune TherapeuticsTurning Point TherapeuticsEnanta PharmaceuticalsGossamer BioIronwood Pharmaceuticals
SymbolNASDAQ:AIMTNASDAQ:TPTXNASDAQ:ENTANASDAQ:GOSSNASDAQ:IRWD
Price Information
Current Price$24.97$36.75$59.31$15.39$9.00
52 Week RangeBuyBuyHoldBuyHold
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyHold
Consensus Price Target$46.88$54.56$101.00$29.25$15.05
% Upside from Price Target87.76% upside48.45% upside70.29% upside90.06% upside67.32% upside
Trade Information
Market Cap$1.52 billion$1.12 billion$1.15 billion$977.34 million$1.37 billion
Beta-0.08N/A0.93N/A1.79
Average Volume1,476,315319,417259,793832,4871,712,682
Sales & Book Value
Annual RevenueN/AN/A$206.63 millionN/A$346.64 million
Price / SalesN/AN/A5.65N/A4.06
CashflowN/AN/A$3.82 per shareN/AN/A
Price / CashN/AN/A15.53N/AN/A
Book Value$5.09 per shareN/A$20.32 per shareN/A($1.27) per share
Price / BookN/AN/A2.92N/A-7.08
Profitability
Net Income$-210,750,000.00N/A$71.95 million$-146,970,000.00$-282,370,000.00
EPS($3.67)N/A$3.48($22.59)($0.95)
Trailing P/E RatioN/A0.0017.04N/AN/A
Forward P/E RatioN/AN/AN/AN/A17.30
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A29.22%N/A-64.48%
Return on Equity (ROE)-89.68%N/A15.16%N/AN/A
Return on Assets (ROA)-71.14%N/A14.33%N/A-25.05%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.24%0.01%N/A0.09%N/A
Current Ratio5.80%32.35%22.01%17.80%1.99%
Quick Ratio5.80%32.35%22.01%17.80%1.98%
Ownership Information
Institutional Ownership Percentage78.06%58.17%88.62%54.64%N/A
Insider Ownership Percentage13.75%N/A11.35%23.30%5.90%
Miscellaneous
Employees22850113118515
Shares Outstanding62.67 million31.34 million19.68 million65.93 million156.49 million
Next Earnings Date11/14/2019 (Estimated)11/5/2019 (Estimated)11/25/2019 (Estimated)11/14/2019 (Estimated)11/5/2019 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
 Aimmune TherapeuticsTurning Point TherapeuticsEnanta PharmaceuticalsGossamer BioIronwood Pharmaceuticals

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel